Generic developing pharmaceutical companies have been in ligation in order to invalidate a subsequent patent of Crestor
On August 17, according to the pharmaceutical industry, generic developing pharmaceutical companies which manufacture generic of Crestor that released in April, has been in ligation in order to invalidate a subsequent patent registered by the original company. This is because it is difficult to g...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
